Relationship between clinical features and serum complements levels in anti-ACHR antibody-positive myasthenia gravis

Background: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ). Anti-acetylcholine receptor (AChR) antibody, which is confirmed in 85-90% of MG patients, activates complements and induces the formation of membrane attack complex (MAC) which ultimately leads to NMJ destruction and muscle weakness.